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Introduction
Graves’ orbitopathy (GO) is the most common cause of
exophthalmos. The most severe complication of GO is
optic neuropathy. Endogenous hypercortisolism (Cushing
syndrome) can also lead to exophthalmos by stimulating
the proliferation of retrobulbar adipose tissue. Cases of the
optic nerve neuropathy due to the glucocorticoids treat-
ment have not been described, so far.
Case report
A 31-year-old woman with orbitopathy due to Graves’ dis-
ease, after radioiodine treatment, treated for hypothyroid-
ism with sufficient dose of levothyroxine, was referred to
the Department of Endocrinology due to the progressive
deterioration of visual acuity and impaired right-eye colour
vision. This symptoms have developed for the last two
months. On admission, there were features of active orbi-
topathy (5/7 points on CAS scale), permanent double
vision, without exophthalmos. MRI examination revealed
active inflammatory process, proliferation of retrobulbar
fat, without thickening of oculomotor muscles. Diagnosis
of optic nerve neuropathy was established and the patient
was treated with high-doses of intravenous (iv) methyl-
prednisolone (MP) pulses - 1g for three consecutive days.
After this treatment visual acuity did not improve. The
decision of performing urgent bilateral endoscopic decom-
pression was made. The surgical operation restored full
visual acuity and colour vision. The clinical features of
active inflammatory process receded. Diplopia was still
present but only when the patient was looking to the left.
The decompression surgery was followed by weekly
administration of iv MP pulses (6x500mg, 6x250mg). Dur-
ing the treatment, after the eighth pulse, symptoms of
optic nerve neuropathy relapsed in the form of sudden
aggravation of visual acuity and impaired colour vision.
The clinical activity score remained low (1-2/7). The sec-
ond bilateral, intranasal, endoscopic decompression was
performed, resulting in gradual return of full sharpness of
vision. A probable cause of the recurrence of neuropathy
symptoms was the proliferation of adipose tissue as a com-
plication of treatment with MP.
Conclusions
High dose iv MP pulse therapy is a highly effective immu-
nosuppressive treatment used in various inflammatory and
autoimmune diseases e.g. active, moderate to severe GO
and neuropathy due to GO. It remains to be proven,
whether in some cases, the administration of MP can
cause orbitopathy as well as may lead to the deterioration
of its severity, including optic nerve neuropathy, probably
as a result of the proliferation of adipose tissue.
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